drugset / Trial / NCT06352892
A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective of the study is to assess the pharmacokinetics (PK) of Maridebart Cafraglutide after a single subcutaneous (SC) administration in overweight or obese Chinese participants.
Timeline
- Start
- 2024-04-25
- Primary completion
- 2024-08-27
- Completion
- 2024-08-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maridebart Cafraglutide | Unknown | — | Subcutaneous |